Overview

Phase II Pharmacokinetics Study of CAM2038

Status:
Completed

Trial end date:
2017-07-03

Target enrollment:

Participant gender:

Summary

Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.

Phase:

Phase 2

Details

Lead Sponsor:

Braeburn Pharmaceuticals

Treatments:

Buprenorphine